Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies

Sanjay Popat^{1

2}, Myung-Ju Ahn³, Simon Ekman^{4

5}, Natasha B Leighl⁶, Suresh S Ramalingam⁷, Thanyanan Reungwetwattana⁸, Shankar Siva^{9

10}, Masahiro Tsuboi¹¹, Yi-Long Wu¹², James Chih-Hsin Yang¹³

Affiliations

¹ Lung Unit, Royal Marsden Hospital, London, UK. sanjay.popat@rmh.nhs.uk.
² Division of Clinical Studies, Institute of Cancer Research, London, UK. sanjay.popat@rmh.nhs.uk.
³ Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
⁴ Theme Cancer, Thoracic Oncology Center, Karolinska University Hospital, Stockholm, Sweden.
⁵ Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
⁶ Medical Oncology, Princess Margaret Cancer Center, Toronto, Canada.
⁷ Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.
⁸ Division of Medical Oncology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, 10400, Thailand.
⁹ Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
¹⁰ Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
¹¹ Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
¹² Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.
¹³ Department of Oncology, National Taiwan University Hospital Cancer Center, Taipei, Taiwan.

Published Erratum

Sanjay Popat et al. Target Oncol. 2023 Mar.

. 2023 Mar;18(2):311.

doi: 10.1007/s11523-023-00947-9.

¹ Lung Unit, Royal Marsden Hospital, London, UK. sanjay.popat@rmh.nhs.uk.
² Division of Clinical Studies, Institute of Cancer Research, London, UK. sanjay.popat@rmh.nhs.uk.
³ Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
⁴ Theme Cancer, Thoracic Oncology Center, Karolinska University Hospital, Stockholm, Sweden.
⁵ Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
⁶ Medical Oncology, Princess Margaret Cancer Center, Toronto, Canada.
⁷ Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.
⁸ Division of Medical Oncology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, 10400, Thailand.
⁹ Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
¹⁰ Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
¹¹ Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
¹² Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.
¹³ Department of Oncology, National Taiwan University Hospital Cancer Center, Taipei, Taiwan.

No abstract available

Erratum for

Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies.
Popat S, Ahn MJ, Ekman S, Leighl NB, Ramalingam SS, Reungwetwattana T, Siva S, Tsuboi M, Wu YL, Yang JC. Popat S, et al. Target Oncol. 2023 Jan;18(1):9-24. doi: 10.1007/s11523-022-00941-7. Epub 2023 Jan 18. Target Oncol. 2023. PMID: 36652172 Review.